ReviewCurrent opinion in drug discovery & development2010
Advances in protein NMR provided by the NIGMS Protein Structure Initiative: impact on drug discovery.
Review in Current opinion in drug discovery & development, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- AlphaFold Models of Small Proteins Rival the Accuracy of Solution NMR Structures.Frontiers in molecular biosciences · 2022Article
- Spatially selective heteronuclear multiple-quantum coherence spectroscopy for biomolecular NMR studies.Chemphyschem : a European journal of chemical physics and physical chemistry · 2014Article
- Approaches to automated protein crystal harvesting.Acta crystallographica. Section F, Structural biology communications · 2014Article
- Exploring chemical space for drug discovery using the chemical universe database.ACS chemical neuroscience · 2012Review
- The Protein Structure Initiative: achievements and visions for the future.F1000 biology reports · 2012Article
- First experiences with semi-autonomous robotic harvesting of protein crystals.Journal of structural and functional genomics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Rational drug design relies on the 3D structures of biological macromolecules, with a particular emphasis on proteins. The structural genomics-based high-throughput structure determination platforms established by the Protein Structure Initiative (PSI) of the National Institute of General Medical Science (NIGMS) of the NIH are uniquely suited to provide these structures. NMR plays a critical role in structure determination because many important protein targets do not form the single crystals required for X-ray diffraction. NMR can provide valuable structural and dynamic information on proteins and their drug complexes that cannot be obtained with X-ray crystallography. This review discusses recent advances in NMR that have been driven by structural genomics projects. These advances suggest that the future discovery and design of drugs can increasingly rely on protocols using NMR approaches for the rapid and accurate determination of structures.
Indexed as
Identifiers
20443167PMC4002360W345366157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.